Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
CA 2369119 A1 · Owner: Statens Serum Institut · Inventors: Fomsgaard, Anders
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a method for producing a nucleotide sequence construct with optimized codons for an HIV genetic vaccine based on a primary early HIV isolate. Specific such nucleotide sequence construct are the synthetic envelope BX08 constructs. The invention further relates to the medical use of such constructs for the treatment and prophylaxis of HIV through DNA vaccine and for diagnostics.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 27, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 27, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 27, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.